Cargando…

Progression in patients with low- and intermediate-1-risk del(5q) myelodysplastic syndromes is predicted by a limited subset of mutations

A high proportion of patients with lower-risk del(5q) myelodysplastic syndromes will respond to treatment with lenalidomide. The median duration of transfusion-independence is 2 years with some long-lasting responses, but almost 40% of patients progress to acute leukemia by 5 years after starting tr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Scharenberg, Christian, Giai, Valentina, Pellagatti, Andrea, Saft, Leonie, Dimitriou, Marios, Jansson, Monika, Jädersten, Martin, Grandien, Alf, Douagi, Iyadh, Neuberg, Donna S., LeBlanc, Katarina, Boultwood, Jacqueline, Karimi, Mohsen, Jacobsen, Sten Eirik W., Woll, Petter S., Hellström-Lindberg, Eva
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ferrata Storti Foundation 2017
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5394951/ https://www.ncbi.nlm.nih.gov/pubmed/27884971 http://dx.doi.org/10.3324/haematol.2016.152025

Ejemplares similares

Perturbed hematopoietic stem and progenitor cell hierarchy in myelodysplastic syndromes patients with monosomy 7 as the sole cytogenetic abnormality
por: Dimitriou, Marios, et al.
Publicado: (2016)

A three-dimensional in vitro model of erythropoiesis recapitulates erythroid failure in myelodysplastic syndromes
por: Elvarsdóttir, Edda María, et al.
Publicado: (2019)

Targeting stem cells in myelodysplastic syndromes and acute myeloid leukemia
por: Woll, Petter S., et al.
Publicado: (2022)

The extent of residual WT HSPCs is associated with the degree of anemia in patients with SF3B1-mutated MDS-RS
por: Hofman, Isabel Juliana F., et al.
Publicado: (2022)

Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes
por: Gerstung, Moritz, et al.
Publicado: (2015)

Haploinsufficiency of RPS14 in 5q− syndrome is associated with deregulation of ribosomal- and translation-related genes
por: Pellagatti, Andrea, et al.
Publicado: (2008)

Myelodysplastic syndromes
por: Hellström Lindberg, Eva
Publicado: (2018)

Recent Advances in the 5q- Syndrome
por: Pellagatti, Andrea, et al.
Publicado: (2015)

The impact of spliceosome mutations in MDS
por: Boultwood, Jacqueline, et al.
Publicado: (2019)

The Role of the Iron Transporter ABCB7 in Refractory Anemia with Ring Sideroblasts
por: Boultwood, Jacqueline, et al.
Publicado: (2008)

“Randomized phase II study of azacitidine ± lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)”
por: Rasmussen, Bengt, et al.
Publicado: (2022)

Mutations in histone modulators are associated with prolonged survival during azacitidine therapy
por: Tobiasson, Magnus, et al.
Publicado: (2016)

The U2AF1(S34F) mutation induces lineage-specific splicing alterations in myelodysplastic syndromes
por: Yip, Bon Ham, et al.
Publicado: (2017)

CSNK1A1 mutations and gene expression analysis in myelodysplastic syndromes with del(5q)
por: Bello, Erica, et al.
Publicado: (2015)

Myelodysplastic syndromes: moving towards personalized management
por: Hellström-Lindberg, Eva, et al.
Publicado: (2020)

Pseudouridine-modified tRNA fragments repress aberrant protein synthesis and predict leukaemic progression in myelodysplastic syndrome
por: Guzzi, Nicola, et al.
Publicado: (2022)

Integrated Genomic and Transcriptomic Analysis Improves Disease Classification and Risk Stratification of MDS with Ring Sideroblasts
por: Todisco, Gabriele, et al.
Publicado: (2023)

Suboptimal Immune Reconstitution in Vertically HIV Infected Children: A View on How HIV Replication and Timing of HAART Initiation Can Impact on T and B-cell Compartment
por: Cotugno, Nicola, et al.
Publicado: (2012)

P713: EXPLORING CLONAL COMPETITION THROUGH 12-YEAR FOLLOW-UP OF AN MDS-RS PATIENT WITH DUAL SF3B1 MUTATIONS
por: Moura, Pedro, et al.
Publicado: (2023)

Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms
por: Malcovati, Luca, et al.
Publicado: (2011)

GFI1(36N) as a therapeutic and prognostic marker for myelodysplastic syndrome
por: Botezatu, Lacramioara, et al.
Publicado: (2016)

Targeted resequencing analysis of 31 genes commonly mutated in myeloid disorders in serial samples from myelodysplastic syndrome patients showing disease progression
por: Pellagatti, A, et al.
Publicado: (2016)

Aged healthy mice acquire clonal hematopoiesis mutations
por: Chin, Desmond Wai Loon, et al.
Publicado: (2022)

TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups
por: Haase, Detlef, et al.
Publicado: (2019)

A miRNA screening identifies miR-192-5p as associated with response to azacitidine and lenalidomide therapy in myelodysplastic syndromes
por: Mongiorgi, Sara, et al.
Publicado: (2023)

The cell-type specific transcriptome in human adipose tissue and influence of obesity on adipocyte progenitors
por: Ehrlund, Anna, et al.
Publicado: (2017)

Cryptic splicing events in the iron transporter ABCB7 and other key target genes in SF3B1-mutant myelodysplastic syndromes
por: Dolatshad, H, et al.
Publicado: (2016)

Therapy-related MDS dissected based on primary disease and treatment—a nationwide perspective
por: Moreno Berggren, Daniel, et al.
Publicado: (2023)

Imprint of 5-azacytidine on the natural killer cell repertoire during systemic treatment for high-risk myelodysplastic syndrome
por: Sohlberg, Ebba, et al.
Publicado: (2015)

A mutation in the H/ACA box of telomerase RNA component gene (TERC) in a young patient with myelodysplastic syndrome
por: Ueda, Yasutaka, et al.
Publicado: (2014)

Transformation of mouse T cells requires MYC and AKT activity in conjunction with inhibition of intrinsic apoptosis
por: Högstrand, Kari, et al.
Publicado: (2018)

Disruption of SF3B1 results in deregulated expression and splicing of key genes and pathways in myelodysplastic syndrome hematopoietic stem and progenitor cells
por: Dolatshad, H, et al.
Publicado: (2015)

Disruption of SF3B1 results in deregulated expression and splicing of key genes and pathways in myelodysplastic syndrome hematopoietic stem and progenitor cells
por: Dolatshad, H, et al.
Publicado: (2015)

Case Report: Whole genome sequencing identifies CCDC88C as a novel JAK2 fusion partner in pediatric T-cell acute lymphoblastic leukemia
por: Krstic, Aleksandra, et al.
Publicado: (2023)

Tumor necrosis factor restricts hematopoietic stem cell activity in mice: involvement of two distinct receptors
por: Pronk, Cornelis J.H., et al.
Publicado: (2011)

Aberrant splicing of genes involved in haemoglobin synthesis and impaired terminal erythroid maturation in SF3B1 mutated refractory anaemia with ring sideroblasts
por: Conte, Simona, et al.
Publicado: (2015)

A series of case studies illustrating the role of flow cytometry in the diagnostic work‐up of myelodysplastic syndromes
por: Westers, Theresia M., et al.
Publicado: (2022)

S173: RETROSPECTIVE STUDY OF LENALIDOMIDE DISCONTINUATION IN PATIENTS WITH MYELODYSPLASTIC SYNDROME HARBORING DEL(5Q). A HARMONY ALLIANCE STUDY
por: Crisà, Elena, et al.
Publicado: (2023)

Differential Transcriptional Reprogramming by Wild Type and Lymphoma-Associated Mutant MYC Proteins as B-Cells Convert to a Lymphoma Phenotype
por: Mahani, Amir, et al.
Publicado: (2021)

Activation of targetable inflammatory immune signaling is seen in myelodysplastic syndromes with SF3B1 mutations
por: Choudhary, Gaurav S, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_i3p36m5ept66gio7bthqbvisf6